instruction:
Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.
question:
Context: After a tough win over the Texans, the Steelers stayed home for a game against the Colts. In the first quarter, the Colts scored first as Adam Vinatieri nailed a 31-yard field goal for a 3-0 lead. However, the Steelers took the lead later on in the quarter when Ben Roethlisberger found Markus Wheaton on an 18-yard TD pass for a 7-3 game. In the 2nd quarter, the Steelers would score again increasing their lead as Roethlisberger found Martavis Bryant on a 5-yard TD pass for a 14-3 game. This was followed by William Gay picking off Andrew Luck and returning it 33 yards for a TD as they increased their lead to 21-3. The Colts however responded as Andrew Luck threw a 21-yard TD pass to Dwayne Allen for a 21-10 game. However, the Steelers pulled away as Roethlisberger would find Antonio Brown on 2 consecutive TD passes: from 8 and 47 yards out to increase their lead at first from 28-10 to 35-10. The Colts responded with 10 straight points first being Luck who found T. Y. Hilton on a 28-yard TD Pass for a 35-17 game followed by Vinatieri kicking a 23-yard field goal before halftime to make the score 35-20. The Steelers went back to work in the 3rd quarter as Roethlisberger and Bryant hooked up again on a 2-yard TD pass to increase their lead making the score 42-20. The Colts however were able to come within 8 later on when Ahmad Bradshaw ran for a 12-yard TD followed by Luck finding Donte Moncrief on a 31-yard TD pass to make the score 42-27 and then 42-34. In the 4th quarter, it was all Steelers when a penalty was enforced on Luck in the end zone for a safety making the score 44-34. The Steelers were able to seal the game later on when Roethlisberger found Heath Miller on an 11-yard TD pass for a final score of 51-34. Roethlisberger set franchise records with 522 yards passing and six touchdowns while picking up his 100th victory in his 150th start. Roethlisberger's yardage total was the fourth highest in NFL history. He became the first player in NFL history to go over 500 yards passing twice as the Steelers won consecutive games for the first time this season.
Question: Which team gave up the ball in the first half?
answer:
colts

question:
Context: Francesco Gessi (20 January 1588 -- 1649) was an Italian painter of the Baroque period, active mainly in Bologna.
Question: In what city did Francesco Gessi die?
answer:
bologna

question:
Context: To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis. Three multicenter, randomized, double-masked, placebo-controlled, dose-ranging phase III studies: SHIELD, INSURE, and ENDURE. A total of 118 patients with Behcet's uveitis (SHIELD study); 31 patients with active, noninfectious, non-Behcet's uveitis (INSURE study); and 125 patients with quiescent, noninfectious, non-Behcet's uveitis (ENDURE study) were enrolled. After an initial subcutaneous (s.c.) loading phase in each treatment arm, patients received s.c. maintenance therapy with secukinumab 300 mg every 2 weeks (q2w), secukinumab 300 mg monthly (q4w), or placebo in the SHIELD study; secukinumab 300 mg q2w, secukinumab 300 mg q4w, secukinumab 150 mg q4w, or placebo in the INSURE study; or secukinumab 300 mg q2w, secukinumab 300 mg q4w, secukinumab 150 mg q4w, or placebo in the ENDURE study. Reduction of uveitis recurrence or vitreous haze score during withdrawal of concomitant immunosuppressive medication (ISM). Other end points included best-corrected visual acuity, ISM use (expressed as a standardized ISM score), and safety outcomes. After completion or early termination of each trial, there were no statistically significant differences in uveitis recurrence between the secukinumab treatment groups and placebo groups in any study. Secukinumab was associated with a significant reduction in mean total post-baseline ISM score (P = 0.019; 300 mg q4w vs. placebo) in the SHIELD study. Likewise, secukinumab was associated with a greater median reduction in ISM score versus placebo in the INSURE study, although no statistical analysis of the difference was conducted because of the small sample size. Overall, there was no loss in visual acuity reported in any treatment group during follow-up in all 3 studies. According to descriptive safety statistics, the frequencies of ocular and nonocular adverse events seemed to be slightly higher among secukinumab groups versus placebo across the 3 studies. The primary efficacy end points of the 3 studies were not met. The secondary efficacy data from these studies suggest a beneficial effect of secukinumab in reducing the use of concomitant ISM.
Question: Which molecule is targeted by a monoclonal antibody Secukinumab?
answer:
interleukin-17a